RESCAP by Alloksys Life Sciences for Burns: Likelihood of Approval
Pharmaceutical Technology
SEPTEMBER 9, 2024
RESCAP is under clinical development by Alloksys Life Sciences and currently in Phase II for Burns.
Clinical Development Development Life Science 
Rivus raises $132m to advance clinical development of obesity treatment
Pharmaceutical Technology
SEPTEMBER 23, 2022
Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the treatment of obesity and cardio-metabolic disorders. RA Capital Management led the financing round, which also saw participation from Bain Capital Life Sciences and BB Biotech.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.
Life Science 
162
162 
Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan Aesthetics – Xtalks Life Science Podcast Ep. 134
XTalks
NOVEMBER 1, 2023
Stephanie Manson Brown, VP & Head of Clinical Development & Scientific Innovation of R&D at Allergan Aesthetics at AbbVie. She also spoke about clinical trials in the space, including Allergan Aesthetics’ commitment to increasing diversity in trials and developing products that do not cater to any one beauty standard.
Life Science 101
101 
How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinical trials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. And that has a lot of downstream consequences.” This trend, which Dr.
Upstream Bio raises funds to advance clinical development of UPB-101
Pharmaceutical Technology
JUNE 9, 2023
Co-led by Venrock Healthcare Capital Partners (Venrock) and Enavate Sciences, the financing round has seen participation from new investors Wellington Management and Bain Capital Life Sciences. It is also preparing for a swift transition to Phase III development.
Bringing the Tech Revolution to Medicine with Digital Therapeutics ft. Click Therapeutics’ CMO Dr. Shaheen Lakhan — Xtalks Life Science Podcast Ep. 184
XTalks
NOVEMBER 13, 2024
In this episode, Ayesha spoke with Shaheen Lakhan, MD, PhD, Chief Medical and Scientific Officer, Click Therapeutics , a company focused on developing software as prescription medical treatments for people with unmet medical needs. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Life Science 59
59 
Cloudbyz Recognized in Everest Group’s 2024 PEAK Matrix® for Life Sciences CTMS Solution
Cloudbyz
NOVEMBER 22, 2024
We are deeply honored to be recognized in Everest Group’s PEAK Matrix® for Life Sciences CTMS solutions,” said Dinesh Kashyap, CEO and Founder of Cloudbyz. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”
Life Science 52
52 
Why Should Companies Use Digital Endpoints Across Clinical Development?
XTalks
MAY 28, 2024
Our discussion delved into the potential of DHTs to reshape how clinical trials are conducted, making them not only faster and less costly but also more patient-centric and reflective of real-world outcomes. This approach can speed up development and improve data quality, potentially leading to more effective and personalized therapies.
Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership
BioTech 365
SEPTEMBER 29, 2021
Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership CAMBRIDGE & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage … Continue reading → (..)
Life Science 52
52 
Bios Health Group launches innovation circle to advance life sciences
Outsourcing Pharma
APRIL 16, 2024
Bios Health Group, a leading strategic and investment partner for life science companies and investors, has officially introduced the Bios Innovation Circle.
Life Science 80
80 
Parkinson’s Disease: Link With Melanoma + Drug Development – Xtalks Life Science Podcast Ep. 6
XTalks
APRIL 14, 2021
FDA-mandated clinical holds, strategic partnership breakups and $800 million biotech acquisitions. She shares how well the firms have weathered the COVID-19 pandemic, and the team discusses the outlook for the drug development industry in general. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Life Science 92
92 
Cloudbyz Recognized in Everest Group’s 2024 PEAK Matrix® for Life Sciences EDC Solutions
Cloudbyz
SEPTEMBER 11, 2024
This prestigious recognition positions Cloudbyz among the top performers in delivering intuitive and scalable EDC solutions to life sciences organizations worldwide. This prestigious recognition positions Cloudbyz among the top performers in delivering intuitive and scalable EDC solutions to life sciences organizations worldwide.
Life Science 52
52 
Cloud robotics labs are accelerating drug discovery and development
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development.
Development 311
311 
Forge Biologics joins BGTC for new AAV gene therapies development
Pharmaceutical Technology
MAY 24, 2023
Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.
Gene Therapy 242
242 
IWD: Spotlight on women in life sciences
pharmaphorum
MARCH 8, 2022
How did you get into life sciences? After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. What has your career path been?
Life Science 98
98 
Bios Health Group enters life sciences offering multiple solutions to pharma industry
Outsourcing Pharma
AUGUST 22, 2023
Those in the life sciences industry needing some creative input can now turn to Bios Health Group who have recently launched into the space.
Life Science 81
81 
Dr. Lahar Mehta Speaks About New Trial to Evaluate ALS Drug for Progressive Supranuclear Palsy – Xtalks Life Science Podcast Ep. 136
XTalks
NOVEMBER 15, 2023
This episode features an interview with Dr. Lahar Mehta, Head of Global Clinical Development at Amylyx Pharmaceuticals, who spoke to Xtalks about Amylyx’s clinical trial design of ORION, a Phase III Global Study of AMX0035 (Relyvrio) in Progressive Supranuclear Palsy (PSP).
Life Science 52
52 
Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from Merck – Xtalks Life Science Podcast Ep. 140
XTalks
DECEMBER 13, 2023
This episode features an interview with vaccine scientists and executives from Vaccines Global Clinical Development at Merck, Dr. Heather Platt, MD, Distinguished Scientist and Pneumococcal Vaccine Lead; and Dr. Ulrike Buchwald, MD, Scientific Associate Vice President, Global Clinical Research and Pneumococcal Vaccine Section Head.
Life Science 52
52 
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates
BioTech 365
MAY 12, 2021
Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates Kezar Life Sciences Reports First Quarter Financial Results and Provides Business Updates KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in … Continue reading →
Life Science 40
40 
atai invests $50m in Beckley Psytech
pharmaphorum
JANUARY 5, 2024
Beckley Psytech has announced that is has received substantial strategic investment from atai Life Sciences, totalling $50 million, to accelerate the clinical development of short-duration psychedelics.
Life Science 97
97 
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates
BioTech 365
MARCH 11, 2021
Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates KZR-616 clinical development in three severe autoimmune diseases … Continue reading →
Life Science 52
52 
Syneos Health Welcomes Costa Panagos as New CEO
XTalks
OCTOBER 24, 2024
Panagos, an industry veteran with extensive experience in the healthcare and life sciences sector, takes over from Colin Shannon, who served as CEO for one year following the company’s acquisition by a consortium of private equity firms. Shannon has now been appointed Executive Chairman of Syneos.
Life Science 102
102 
4 Life Science Trends To Pay Attention To in 2021
XTalks
JANUARY 5, 2021
The pandemic itself will also continue to spur innovations and changes such as greater shifts towards decentralized clinical trials and patient-centric approaches. In addition to vaccines, there are handfuls of drugs currently being evaluated in clinical trials for the treatment of COVID-19. 1. COVID-19 Pandemic: An Evolving Era.
Life Science 98
98 
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma
The Pharma Data
MARCH 15, 2022
Investment will accelerate the overall Sarclisa ® development program Sanofi will continue to fully manage the clinical program and retain full rights and control of Sarclisa ® (isatuximab). to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience.
Life Science 52
52 
Cognizant and Boehringer Ingelheim partner to speed delivery of new medicines
Pharmaceutical Technology
APRIL 12, 2023
Cognizant and Boehringer Ingelheim are collaborating on an integrated cloud platform to enhance the speed and quality of medicinal therapy development. Cognizant will leverage the Veeva Development Cloud platform to help Boehringer Ingelheim to merge medicinal development processes and data into a connected technology ecosystem.
Medicine 130
130 
Alkeus raises funds to launch Stargardt disease therapy gildeuretinol
Pharmaceutical Technology
JUNE 6, 2023
Led by Bain Capital Life Sciences, the financing round has also seen participation from Sofinnova Investments, TCGX and Wellington Management. Gildeuretinol is the first and only medicine in clinical development to treat Stargardt disease by reducing vitamin A dimerization in the eye, without affecting normal vision.
Genetics 279
279 
Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
The Pharma Data
NOVEMBER 30, 2020
Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences. About Tiziana Life Sciences. NEW YORK and LONDON, Dec.
Life Science 40
40 
The Science of Sleep: Unmet Needs and Treatments for Narcolepsy ft. Avadel Pharma’s Dr. Jennifer Gudeman
XTalks
SEPTEMBER 4, 2024
In this episode, Ayesha spoke with Jennifer Gudeman, Pharm D, Senior Vice President, Medical and Clinical Affairs, Avadel Pharmaceuticals , a biopharmaceutical company working on innovative solutions to the development of medications that disrupt treatment paradigms and address unmet needs. Dr. Gudeman joined Avadel in 2020.
Life Science 52
52 
Copado lands $96m in Series B funding to fuel life-sciences digital transformation
Outsourcing Pharma
MARCH 9, 2021
The development technology firm plans to use the funds, sourced from a wide range of investors, to expand its dev-ops platform and expand its global reach.
Life Science 73
73 
Research charity crisis affects the whole development ecosystem
pharmaphorum
MARCH 17, 2021
Charity-funded medical research is a vital cog in the clinical development machine – but COVID-19 has left it facing an existential threat. It means groups have had to take difficult decisions around research funding – decisions that could have long-term reverberations for the whole clinical development sector. “We
Research 98
98 
Health Canada accepts Paladin’s NDS for epilepsy-linked seizure therapy
Pharmaceutical Technology
AUGUST 9, 2022
In the clinical development programme, 1,944 epilepsy patients received cenobamate treatment. Discovered by SK Biopharmaceuticals and SK life science, cenobamate is a new small molecule anti-seizure therapy.
Life Science 246
246 
Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder
The Pharma Data
JANUARY 14, 2021
I am pleased that we at Awakn are spear-heading the global initiative to develop new efficacious strategies for tackling this condition. ” About Awakn Life Sciences. Our patients deserve the best that cutting-edge psychopharmacology research can offer.” ” The study team is chaired by Prof.
Life Science 52
52 
GSK’s Maria Reyes Boceta-Muñoz Talks Vaccine Development in a Post-Pandemic World
XTalks
SEPTEMBER 5, 2023
Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?
Vaccination 83
83 
HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald
XTalks
OCTOBER 4, 2023
How do you make strategic decisions around products that are in the early stage of development and are still years from regulatory approval and launch? In the specialized, personalized and advanced medicines spaces, this work should start very early — as early as Phase I or Phase II of clinical development.
Marketing 105
105 
Providing the Blueprint for Gen AI Adoption in Clinical Trials
ACRP blog
OCTOBER 10, 2024
The same is true in life sciences. As the technology develops, however, it will offer more opportunities to expedite drug discovery processes, streamline clinical trials, and speed up regulatory approvals. MGI puts the value of this contribution to clinical development at $15 billion to $25 b illion.
Medidata Recognized as a Leader in Everest Group’s Inaugural Electronic Data Capture Peak Matrix® Assessment
XTalks
SEPTEMBER 27, 2024
Medidata , a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a Leader in Everest Group‘s first-ever PEAK Matrix® Assessment for Electronic Data Capture (EDC) in life sciences.
Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
The Pharma Data
SEPTEMBER 29, 2021
The new FIND-CKD study extends our clinical research for finerenone to a non-diabetic population where the unmet need is high for brand spanking new treatments to delay disease progression.”. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.
Transforming Clinical Research: A Conversation with Morgan Hanger, Executive Director of CTTI
XTalks
OCTOBER 23, 2024
Hanger encourages new clinical trial professionals to embrace innovation and stay patient-focused. She hopes her work at CTTI will influence the development of a clinical trial system that is more efficient, inclusive and better aligned with patient needs. Tune in to learn how CTTI is leading efforts to reshape clinical trials.
Innovating Approaches to Target Diseases of Aging with Jerry McLaughlin, CEO of Life Biosciences
XTalks
JULY 25, 2024
In this episode, Ayesha spoke with Jerry McLaughlin, chief executive officer and board member of Life Biosciences , a company advancing innovative cellular rejuvenation platforms to reverse diseases of aging. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Life Science 59
59 
Numab raises $110m to develop cancer bispecific antibodies
pharmaphorum
MAY 20, 2021
Switzerland’s Numab has raised 100 million Swiss francs – around $110 million – in Series C financing to develop bispecific antibodies for cancer and inflammation, with Novo Noldings and HBM Partners co-leading the investor syndicate. The post Numab raises $110m to develop cancer bispecific antibodies appeared first on.
Antibody 52
52 
How is Oracle technology helping CROs enable pharma to get trials up and running?
Outsourcing Pharma
APRIL 15, 2024
Michael Fronstin, global head of client partnership and commercialization at the company said the combination of Oracleâs life sciences expertise and platform technology help CROs win more business and run trials more efficiently.
Life Science 95
95 
New White Paper on Advanced Therapies Sets up Developers for Success
XTalks
OCTOBER 7, 2020
However, these complex treatments present challenges to developers over and above the well-documented hurdles of rare-disease research. The Xtalks White Paper, The Intersection of Rare Disease and Advanced Therapies: What it Means for Clinical Development , is available for free download. Adjusting for COVID-19.
Development 98
98 
Switzerland’s Synendos raises CHF 20m for CNS drug development
pharmaphorum
NOVEMBER 12, 2020
Swiss startup Synendos Therapeutics has raised CHF 20 million (almost $22 million) in first-round financing that will be used to develop its endocannabinoid drugs for central nervous system disorders. Synendos says the cash will allow it to take its lead product SYT-510 through preclinical and proof-of-concept clinical development.
Development 106
106 
Let's personalize your content